Remember, our flagship PII trial had doses switched...This is a FDA investigation now...
When there is such an event the FDA must get involved and investigations completed. Is there really any wonder why we haven't heard anything on the topic? Ongoing investigation is the reason. These things can last years...luckily Bavituximab is NOT a one trick pony!
Whether or not we were about to partner prior to the discovery is unknown; however, the dose switch 100% changed everything. We are in wait and see until news of the switch and/or new data.
The day traders get stuck and wonder why....because you made the bad trade...it happens.
Just know that either a jump upward is coming on good or great data..or downward if Bavituximab doesn't perform...
Those of us here long enough and who have followed Bavituximab for the 8-9 years it has been in trials believe it works and works well and safely. The undeniable truth is almost upon us....The third and final Phase II Trial data on NSCLC is scheduled for 1st Half 2013 (after being pushed back twice I think).
Hopefully 3's the charm!!!!
Best of Best Data, Partner(s), FDA Approval(s) and Luck!!!
What doesn't work? Sorry, but you said nothing. What is not true? If you are going to try and call me out...call me out.....shed some light....FDA WILL investigate dose switching when involves an FDA accredited facility and involves HUMANS.
So please give some information and not your opinions..as usual.